<DOC>
	<DOC>NCT01625338</DOC>
	<brief_summary>This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) in combination with ribavirin (RBV) with or without pegylated interferon (Peg-IFN) in adults with chronic hepatitis C virus (HCV) infection who participated in a prior Gilead HCV study and have not achieved sustained virologic response (SVR).</brief_summary>
	<brief_title>Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Infection with HCV Must have participated in a prior Gilead HCV study Use of highly effective contraception methods if female of childbearing potential or sexually active male Eligible patients include those in the following received placebo or PegIFN+RBV in a control arm previously participated in a Gileadsponsored HCV study and did not attain sustained virologic response 24 weeks after discontinuation of therapy (SVR24) on a regimen containing: Sofosbuvir+RBV PegIFN and/or RBV in combination with one or more Gilead investigational directacting agents Pregnant or nursing female or male with pregnant female partner Current or prior history of clinical hepatic decompensation Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) Chronic use of systemically administered immunosuppressive agents Active drug abuse Use of any prohibited concomitant medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HCV genotype 2 (GT-2)</keyword>
	<keyword>HCV genotype 3 (GT-3)</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>GS-7977</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Open Label</keyword>
</DOC>